Paper Details

  1. Home
  2. Paper Details

Initial clinical experience with regadenoson, a novel selective A2A agonist for pharmacologic stress single-photon emission computed tomography myocardial perfusion imaging.

Author: BatemanTimothy M, BlackburnBrent, CerqueiraManuel D, HendelRobert C, IskandrianAmi E, LeppoJeffrey A, MahmarianJohn J

Clinical Trial, Phase IIA Phase II trial is a trial that further evaluates the efficacy and safety of a new drug or treatment, whose safety has been confirmed to some extent in a Phase I trial, in a small number of patients.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Multicenter StudyResearch conducted in collaboration with multiple research institutions. It aims to collect a wide range of data and obtain more generalizable results.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Overview

Regadenoson, a selective A2A adenosine receptor agonist, was well-tolerated and as effective as adenosine for detecting and quantifying the extent of hypoperfusion observed with SPECT perfusion imaging. Side effects were generally mild in severity and self-limiting. The 400 microg dose was better tolerated than the 500 microg dose. Phase III clinical trials are now underway.
Paper Details　
Original Abstract of the Article :
OBJECTIVES: Regadenoson, a selective A2A adenosine receptor agonist, was evaluated for tolerability and effectiveness as a pharmacological stress agent for detecting reversible myocardial hypoperfusion when combined with single-photon emission computed tomography (SPECT). BACKGROUND: Adenosine and ...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1016/j.jacc.2005.05.097

データ提供：米国国立医学図書館（NLM）

Regadenoson: A New Oasis in Pharmacologic Stress Testing

The landscape of [pharmacologic stress testing] is vast, with various agents used to induce stress and assess heart health. This study explores the potential of [regadenoson], a novel and selective [A2A adenosine receptor agonist], as a stress agent for [single-photon emission computed tomography (SPECT)] myocardial perfusion imaging. The researchers compared the effectiveness and tolerability of regadenoson to [adenosine], a commonly used stress agent. They found that regadenoson was well-tolerated, with fewer side effects and a simpler administration method. This could make it a more comfortable and convenient option for patients undergoing stress testing.

Regadenoson: A Well-Tolerated and Effective Stress Agent for SPECT Imaging

This study provides strong evidence for the potential of regadenoson as a promising alternative to adenosine for stress testing. It was found to be as effective as adenosine in detecting myocardial hypoperfusion while being better tolerated. This is a significant finding, as it may offer a more comfortable experience for patients and simplify the stress testing process.

Stress Testing and Heart Health: A Camel's Perspective

Stress testing plays a crucial role in understanding heart health. Regadenoson's potential as a well-tolerated and effective stress agent is a welcome addition to the tools available for cardiovascular assessment. It’s important to discuss stress testing options with your doctor and explore the best method for your individual needs.

Dr.Camel's Conclusion

This study showcases the promise of regadenoson as a new oasis in pharmacologic stress testing. It’s a well-tolerated and effective stress agent for SPECT imaging, offering a potentially more comfortable and convenient option for patients. However, more research is needed to establish its long-term benefits and safety.

Date :
  1. Date Completed 2006-03-09
  2. Date Revised 2022-03-30
Further Info :

Pubmed ID

16325044

DOI: Digital Object Identifier

10.1016/j.jacc.2005.05.097

Related Literature

Article Analysis
・Side Effects of dipyridamole
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.